{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:26:17Z","timestamp":1787765177169,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115737"],"award-info":[{"award-number":["70115737"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE6233\/15-1 and HE6233\/16-1"],"award-info":[{"award-number":["HE6233\/15-1 and HE6233\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41375-025-02622-6","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T03:46:43Z","timestamp":1745812003000},"page":"1773-1777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia"],"prefix":"10.1038","volume":"39","author":[{"given":"Rabea","family":"Mecklenbrauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razif","family":"Gabdoulline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piroska","family":"Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa-Kristin","family":"Dallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-1650","authenticated-orcid":false,"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Schwalenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-5024","authenticated-orcid":false,"given":"Andreas","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-2725","authenticated-orcid":false,"given":"Anke","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-3406","authenticated-orcid":false,"given":"Verena","family":"Gaidzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-9862","authenticated-orcid":false,"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6152","authenticated-orcid":false,"given":"Felicitas R.","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2622_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2622_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2622_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2622_CR4","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Comm. 2022;13:4622.","journal-title":"Nat Comm"},{"key":"2622_CR5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","volume":"7","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023;7:1899\u2013909.","journal-title":"Blood Adv"},{"key":"2622_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00774-7","volume":"13","author":"XC Tsai","year":"2023","unstructured":"Tsai XC, Sun K, Lo M, Tien F, Kuo Y, Tseng M, et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J. 2023;13:4.","journal-title":"Blood Cancer J"},{"key":"2622_CR7","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122\u201331.","journal-title":"Blood Adv"},{"key":"2622_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","volume":"37","author":"S Huber","year":"2023","unstructured":"Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, et al. AML classification in the year 2023: How to avoid a Babylonian confusion of languages. Leukemia. 2023;37:1413\u201320.","journal-title":"Leukemia"},{"key":"2622_CR9","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","volume":"37","author":"J Eckardt","year":"2023","unstructured":"Eckardt J, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, et al. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia \u2013 implications for the European LeukemiaNet risk classification. Leukemia. 2023;37:2282\u20135.","journal-title":"Leukemia"},{"key":"2622_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70060","volume":"9","author":"S Cocciardi","year":"2025","unstructured":"Cocciardi S, Saadati M, Wei\u00df N, Sp\u00e4th D, Kapp-Schwoerer S, Schneider I, et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. HemaSphere. 2025;9:e70060.","journal-title":"HemaSphere"},{"key":"2622_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","volume":"8","author":"O Chan","year":"2024","unstructured":"Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, et al. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024;8:1075\u201383.","journal-title":"Blood Adv"},{"key":"2622_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37:1234\u201344.","journal-title":"Leukemia"},{"key":"2622_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00835-5","volume":"13","author":"C Sargas","year":"2023","unstructured":"Sargas C, Ayala R, Larr\u00e1yoz MJ, Chill\u00f3n MC, Rodriguez-Arboli E, Bilbao C, et al. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J. 2023;13:77.","journal-title":"Blood Cancer J"},{"key":"2622_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/leu.2016.345","volume":"31","author":"F Thol","year":"2017","unstructured":"Thol F, Klesse S, K\u00f6hler L, Gabdoulline R, Kloos A, Liebich A, et al. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia. 2017;31:1286\u201395.","journal-title":"Leukemia"},{"key":"2622_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73\u20135.","journal-title":"Biometrics"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02622-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02622-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T02:04:59Z","timestamp":1751249099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02622-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2622"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02622-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AV declares honoraria from BMS\/Celgene, Delbert, Novartis, Pfizer, SOBI and travel support from Amgen. AT declares paid consultancy from BMS and Janssen. WF declares personal fees and non-financial support from AbbVie; grants, personal fees, and non-financial support from Amgen and Pfizer; and personal fees from Jazz Pharmaceuticals, Celgene, MorphoSys, Ariad\/Incyte, Stemline Therapeutics, Clinigen, Daiichi Sankyo, Otsuka and Servier outside the submitted work; in addition, research support from Apis; patent issued with Amgen and support for medical writing for Amgen, Pfizer, and AbbVie. KD declares consultancy with honoraria from AbbVie, Janssen, Jazz, Novartis, Bristol Myers Squibb, Celgene; clinical research funding to institution from Novartis, AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier. HD declares honoraria from AbbVie, AstraZeneca, Gilead, Janssen, Jazz, Pfizer, Servier, Stemline, Syndax; clinical research funding to institution from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier; Travel, accommodations, expenses from Abbvie, Servier. FHH served as an advisor for Novartis, CTI, Celgene\/BMS, Janssen, Abbvie, GSK, Merck and AOP and received research funding from Novartis, Celgene\/BMS and CTI. MH declares honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda, paid consultancy for Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo, and research funding to his institution from Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained according to the Declaration of Helsinki and the study was approved by the local ethics review committee of Hannover Medical School (ethical vote 936-2011 and 1187-2011). Since 2012 all patients were included in the AMLSG-BiO registry. All described methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}